Dan Skovronsky, Eli Lilly CSO

Eli Lil­ly adds $23B in mar­ket cap as in­vestors rush on promise that this will be the amy­loid Alzheimer's drug that works

It’s been decades and dozens of drugs, and most of them failed, but the amy­loid hy­poth­e­sis won’t go gen­tly in­to the night.

While the world …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.